{"certainAgreement":{"otherDetails":"The sponsor can review/embargo results communications prior to public release for a period that is \\>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The 15% response rate was substantially lower than the designed rate of 60% for this trial. Coupled with the influx of new compounds for the treatment of multiple myeloma it was decided that this study should be closed early."},"pointOfContact":{"email":"asksarah@scresearch.net","organization":"Sarah Cannon Research Institute","phone":"1-877-691-7274","title":"John Hainsworth, MD"}}